Related Experiment Videos
[Respiratory syncytial virus infections in children]
1Service de pédiatrie, centre hospitalier général, Longjumeau, France.
Insights
Respiratory syncytial virus (RSV) causes severe respiratory infections in infants and immunocompromised individuals. Current treatments are symptomatic, but understanding the immune response may lead to an effective vaccine.
Area of Science:
- Virology
- Pediatric Infectious Diseases
- Immunology
Context:
- Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory tract infections in children.
- RSV infection poses significant risks for young infants, immunocompromised individuals, and those with congenital heart disease.
- Emerging evidence suggests RSV's role in sudden infant death and post-bronchiolitis asthma development.
Purpose:
- To review the significance of RSV in pediatric respiratory infections.
- To discuss current therapeutic limitations and emerging treatment strategies.
- To highlight the potential for vaccine development based on immune response understanding.
Summary:
- RSV is the primary pathogen identified in pediatric acute lower respiratory tract infections.
- Severe manifestations include severe illness in infants, immune deficiencies, congenital heart disease, and potential links to SIDS and asthma.
- While treatments like ribavirin exist, management is largely supportive, emphasizing the need for preventative measures.
Impact:
- Informs clinicians about the broad impact of RSV in vulnerable pediatric populations.
- Highlights the limitations of current symptomatic treatments for RSV.
- Underscores the critical need for effective RSV vaccines to reduce disease burden and long-term complications.
Abstract:
Respiratory syncytial virus (RSV) is the most frequently isolated agent in acute lower respiratory tract infections in children. It is responsible for severe disease in young infants and patients with immune deficiencies or congenital heart disease, and appears to be involved in sudden death in infancy. There is also some evidence for its involvement in the development of asthma following bronchiolitis. Despite encouraging new therapies (ribavirin, immune globulin, recombinant interferon alfa), treatment remains mainly symptomatic. Hopefully the better understanding of the immune response during VRS infection will allow the development of an effective vaccine in the coming years.